Advisors Capital Management LLC Purchases 597,396 Shares of Kenvue Inc. $KVUE

Advisors Capital Management LLC lifted its position in Kenvue Inc. (NYSE:KVUE) by 64.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,529,161 shares of the company’s stock after buying an additional 597,396 shares during the quarter. Advisors Capital Management LLC owned about 0.08% of Kenvue worth $36,669,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Pittenger & Anderson Inc. bought a new position in Kenvue during the first quarter worth $30,000. TruNorth Capital Management LLC bought a new position in Kenvue during the first quarter worth $36,000. Truvestments Capital LLC acquired a new stake in shares of Kenvue during the first quarter worth $37,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after buying an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its holdings in shares of Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock worth $41,000 after buying an additional 929 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 2.2%

KVUE stock opened at $18.46 on Thursday. The stock has a market capitalization of $35.42 billion, a P/E ratio of 24.94, a price-to-earnings-growth ratio of 2.71 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.15 and a 12 month high of $25.17. The firm has a 50-day moving average price of $21.23 and a 200-day moving average price of $22.30.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The firm’s revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s payout ratio is currently 112.16%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KVUE. Bank of America dropped their target price on Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, July 15th. Canaccord Genuity Group dropped their price target on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 8th. UBS Group dropped their price target on Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, July 17th. Citigroup dropped their price target on Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, July 15th. Finally, Royal Bank Of Canada dropped their price target on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average target price of $24.21.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.